Log In
BCIQ
Print this Print this
 

dusquetide (SGX94, SGX942)

  Manage Alerts
Collapse Summary General Information
Company Soligenix Inc.
DescriptionSynthetic 5-amino acid peptide that acts as an innate defense regulator and binds to sequestosome 1 (SQSTM1; p62)
Molecular Target Sequestosome 1 (SQSTM1) (p62)
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase II
Standard IndicationMucositis
Indication DetailsTreat oral mucositis (OM); Treat severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy
Regulatory Designation U.S. - Fast Track (Treat oral mucositis (OM));
EU - Promising Innovative Medicine (Treat severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy)
PartnerSciClone Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
Get a free BioCentury trial today